Lars Frison

6.2k total citations · 1 hit paper
53 papers, 4.2k citations indexed

About

Lars Frison is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Economics and Econometrics. According to data from OpenAlex, Lars Frison has authored 53 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cardiology and Cardiovascular Medicine, 16 papers in Internal Medicine and 6 papers in Economics and Econometrics. Recurrent topics in Lars Frison's work include Atrial Fibrillation Management and Outcomes (30 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Cardiac electrophysiology and arrhythmias (14 papers). Lars Frison is often cited by papers focused on Atrial Fibrillation Management and Outcomes (30 papers), Venous Thromboembolism Diagnosis and Management (16 papers) and Cardiac electrophysiology and arrhythmias (14 papers). Lars Frison collaborates with scholars based in Sweden, United States and United Kingdom. Lars Frison's co-authors include Gregory Y.H. Lip, Jonathan L. Halperin, Deirdre A. Lane, Stuart Pocock, David Gustafsson, Ulf G. Eriksson, Margaretha Grind, Bengt I. Eriksson, Gunnar Fager and Palle Petersen and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Lars Frison

52 papers receiving 4.0k citations

Hit Papers

Comparative Validation of a Novel Risk Score for Predicti... 2010 2026 2015 2020 2010 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
    2010 770 citations Gregory Y.H. Lip, Lars Frison et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Frison Sweden 27 2.9k 1.8k 676 474 436 53 4.2k
Yves Rosenberg United States 35 6.2k 2.1× 760 0.4× 1.3k 1.9× 223 0.5× 400 0.9× 70 7.9k
Jean‐Pierre Boissel France 22 1.7k 0.6× 394 0.2× 513 0.8× 151 0.3× 270 0.6× 53 2.9k
Steen Z. Abildstrøm Denmark 36 4.1k 1.4× 455 0.3× 1.3k 1.9× 95 0.2× 428 1.0× 110 6.7k
Mátyás Keltai Hungary 30 5.3k 1.8× 900 0.5× 1.8k 2.6× 107 0.2× 501 1.1× 71 7.0k
Maria Grazia Franzosi Italy 31 5.5k 1.9× 1.2k 0.7× 1.8k 2.7× 70 0.1× 1.0k 2.3× 73 8.6k
Marco Alings Netherlands 31 12.8k 4.4× 5.6k 3.2× 985 1.5× 447 0.9× 2.0k 4.6× 87 14.0k
Neena S. Abraham United States 37 2.7k 0.9× 805 0.5× 2.5k 3.7× 98 0.2× 473 1.1× 97 6.0k
Dipak Kotecha United Kingdom 36 4.9k 1.7× 447 0.3× 386 0.6× 112 0.2× 474 1.1× 95 5.7k
Mary T. Brophy United States 28 986 0.3× 189 0.1× 418 0.6× 243 0.5× 221 0.5× 114 3.3k
Harold W. Schnaper United States 30 2.1k 0.7× 266 0.2× 867 1.3× 143 0.3× 115 0.3× 101 3.7k

Countries citing papers authored by Lars Frison

Since Specialization
Citations

This map shows the geographic impact of Lars Frison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Frison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Frison more than expected).

Fields of papers citing papers by Lars Frison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Frison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Frison. The network helps show where Lars Frison may publish in the future.

Co-authorship network of co-authors of Lars Frison

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Frison. A scholar is included among the top collaborators of Lars Frison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Frison. Lars Frison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jongs, Niels, Samvel B. Gasparyan, Lars Frison, et al.. (2025). Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point. Journal of the American Society of Nephrology. 36(12). 2421–2430.
2.
Little, Dustin J., Samvel B. Gasparyan, Patrick Schloemer, et al.. (2023). Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review. Journal of the American Society of Nephrology. 34(12). 1928–1935. 11 indexed citations
3.
Hansson, Kenny M., David Gustafsson, Tor Skärby, Lars Frison, & Erik Berntorp. (2015). Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B. Journal of Thrombosis and Haemostasis. 13(7). 1293–1300. 4 indexed citations
4.
Edvardsson, Nils, et al.. (2012). Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009. Journal of Electrocardiology. 46(1). 29–35. 10 indexed citations
5.
Egstrup, Kenneth, Lennart Bergfeldt, Lars Gullestad, et al.. (2011). QT Response after a Test Dose and during Maintenance Therapy with AZD1305 in Patients with Atrial Fibrillation. American Journal of Cardiovascular Drugs. 11(3). 199–208. 1 indexed citations
6.
Lip, Gregory Y.H., Lars Frison, Jonathan L. Halperin, & Deirdre A. Lane. (2011). Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. Journal of the American College of Cardiology. 58(13). 1398–1399. 3 indexed citations
7.
Lip, Gregory Y.H., et al.. (2008). Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. Journal of Internal Medicine. 264(1). 50–61. 43 indexed citations
8.
Lewis, James H., et al.. (2008). Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. International Journal of Clinical Pharmacology and Therapeutics. 46(7). 327–339. 19 indexed citations
9.
10.
Gomberg‐Maitland, Mardi, Nanette K. Wenger, Jan Feyzi, et al.. (2006). Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. European Heart Journal. 27(16). 1947–1953. 75 indexed citations
11.
Eriksson, Henry, Karin Wåhlander, David Gustafsson, et al.. (2003). A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis. 1(1). 41–47. 128 indexed citations
12.
Bredberg, Eva, Tommy B. Andersson, Lars Frison, et al.. (2003). Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions. Clinical Pharmacokinetics. 42(8). 765–777. 83 indexed citations
13.
Frison, Lars, et al.. (2003). Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor. Clinical Pharmacokinetics. 42(4). 381–392. 83 indexed citations
14.
Fager, Gunnar, et al.. (2003). Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. European Journal of Clinical Pharmacology. 59(4). 283–289. 25 indexed citations
15.
Eriksson, Ulf G., et al.. (2003). Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European Journal of Clinical Pharmacology. 59(1). 35–43. 116 indexed citations
16.
Eriksson, Ulf G., Susanne Johansson, Per‐Ola Attman, et al.. (2003). Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran. Clinical Pharmacokinetics. 42(8). 743–753. 42 indexed citations
17.
Eriksson, Bengt I., Peter Kälebo, Ola E. Dahl, et al.. (2002). Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. The Lancet. 360(9344). 1441–1447. 205 indexed citations
18.
Carlsson, R., et al.. (1997). Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta‐analysis of long‐term omeprazole trials. Alimentary Pharmacology & Therapeutics. 11(3). 473–482. 108 indexed citations
19.
Frison, Lars & Stuart Pocock. (1997). Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. Statistics in Medicine. 16(24). 2855–2872. 39 indexed citations
20.
Frison, Lars & Stuart Pocock. (1992). Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Statistics in Medicine. 11(13). 1685–1704. 466 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yves Rosenberg Breakdown of academic impact, for papers by Jean‐Pierre Boissel Breakdown of academic impact, for papers by Steen Z. Abildstrøm Breakdown of academic impact, for papers by Mátyás Keltai Breakdown of academic impact, for papers by Maria Grazia Franzosi Breakdown of academic impact, for papers by Marco Alings Breakdown of academic impact, for papers by Neena S. Abraham Breakdown of academic impact, for papers by Dipak Kotecha Breakdown of academic impact, for papers by Mary T. Brophy Breakdown of academic impact, for papers by Harold W. Schnaper
Rankless by CCL
2026